Getein Biotech Inc
SSE:603387
Intrinsic Value
Getein Biotech, Inc. engages in the business of medical health industry chain. [ Read More ]
The intrinsic value of one
Getein Biotech Inc
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 9.32 CNY,
Getein Biotech Inc
is
hidden
.
Getein Biotech Inc's market capitalization is 4.7B CNY.
Getein Biotech Inc stock price is 9.32 CNY.
Getein Biotech Inc stock price (9.32 CNY) is 31% less than its Intrinsic Value (13.51 CNY).
Getein Biotech Inc stock price (9.32 CNY) is 47% less than its DCF Value (17.5 CNY). Open DCF Valuation
Getein Biotech Inc stock price (9.32 CNY) is 2% less than its Relative Value (9.51 CNY). Open Relative Valuation
Getein Biotech Inc has upside potential of 301% compared to the average analyst price target.
Open Wall St Estimates
Getein Biotech Inc's ROE (Return on Equity) for the past 12 months is positive and is equal to 9%.
Getein Biotech Inc's Revenue has been growing by 1% per year for the last 3 years.
Getein Biotech Inc's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 7%.
Getein Biotech Inc's ROE (Return on Equity) has decreased in the last 3 years from 18% to 9%.
Getein Biotech Inc's Revenue has dropped by 20% over the past 12 months.
Getein Biotech Inc has positive three-year average ROE (Return on Equity): 19%. The company is efficient at transforming stockholders' equity into net income.
Getein Biotech Inc has positive Operating Income for the last twelve months.
Getein Biotech Inc has positive Net Income for the last twelve months.
Getein Biotech Inc has positive Free Cash Flow for the last twelve months.
Getein Biotech Inc's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 31% to 7%.
Getein Biotech Inc has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (649m CNY).
Getein Biotech Inc has positive three-year average ROIC (Return on Invested Capital): 23%. The company is efficient at using invested capital to generate operating income.
Getein Biotech Inc's short-term assets (2B CNY) exceed its short-term liabilties (978m CNY).
Getein Biotech Inc has positive Gross Profit for the last twelve months.
Getein Biotech Inc's Altman Z-Score is very high and is equal to 3.73.
Getein Biotech Inc's long-term assets (4B CNY) exceed its long-term liabilties (1B CNY).
Getein Biotech Inc's D/E (Debt to Equity) is very low and is equal to 0.25.
Valuation Backtest
Getein Biotech Inc
Run backtest to discover the historical profit from buying and selling
Getein Biotech Inc
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Getein Biotech Inc
Balance Sheet Decomposition
Getein Biotech Inc
| Current Assets | 2.2B |
| Cash & Short-Term Investments | 1B |
| Receivables | 500.8m |
| Other Current Assets | 612.6m |
| Non-Current Assets | 1.6B |
| Long-Term Investments | 641.2m |
| PP&E | 707.8m |
| Intangibles | 208.1m |
| Other Non-Current Assets | 63.4m |
| Current Liabilities | 977.9m |
| Accounts Payable | 129m |
| Accrued Liabilities | 89.8m |
| Short-Term Debt | 646.3m |
| Other Current Liabilities | 112.7m |
| Non-Current Liabilities | 234.4m |
| Long-Term Debt | 2.7m |
| Other Non-Current Liabilities | 231.7m |
Earnings Waterfall
Getein Biotech Inc
|
Revenue
|
1.3B
CNY
|
|
Cost of Revenue
|
-442.5m
CNY
|
|
Gross Profit
|
863.9m
CNY
|
|
Operating Expenses
|
-660.4m
CNY
|
|
Operating Income
|
203.5m
CNY
|
|
Other Expenses
|
40.8m
CNY
|
|
Net Income
|
244.3m
CNY
|
Free Cash Flow Analysis
Getein Biotech Inc
Profitability Score
Profitability Due Diligence
Getein Biotech Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Score
Getein Biotech Inc's profitability score is hidden . The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Getein Biotech Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Score
Getein Biotech Inc's solvency score is hidden . The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Getein Biotech Inc
According to Wall Street analysts, the average 1-year price target for
Getein Biotech Inc
is 37.4 CNY
.
Shareholder Return
Price
Getein Biotech Inc
| Average Annual Return | 3.36% |
| Standard Deviation of Annual Returns | 30.26% |
| Max Drawdown | -65% |
| Market Capitalization | 4.7B CNY |
| Shares Outstanding | 507 153 517 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Getein Biotech Inc
Country
Industry
Market Cap
Dividend Yield
Description
Getein Biotech, Inc. engages in the business of medical health industry chain. The company is headquartered in Nanjing, Jiangsu and currently employs 2,125 full-time employees. The company went IPO on 2017-07-17. Its in vitro diagnostic reagents include Point-of-care Testing (POCT) reagents, chemiluminescence reagents, biochemical reagents, blood cell reagents, hemagglutination reagents and others. Its diagnostic instruments include immunoquantitative analyzer FIA 8000, immunoquantitative analyzer FIA 8600, fluorescence immunoquantitative analyzer Getein 1100, fluorescence immunoquantitative analyzer Getein 1180, automatic biochemical analyzer CM 400, automatic chemiluminescence analyzer MAGICL 6000 and five classification blood cell analyzer BHA-5000, among others. The firm also provides testing and agency services. The firm distributes its products within domestic market and to overseas markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Getein Biotech Inc
stock under the Base Case scenario is
hidden
CNY.
Compared to the current market price of 9.32 CNY,
Getein Biotech Inc
is
hidden
.
You don't have any saved screeners yet
